Tasigna

QT prolongation, sudden deaths have been reported. Correct electrolyte abnormalities prior to initiating; monitor periodically. Obtain ECGs at baseline, after 7 days, then periodically and after dose adjustments. Evaluate cardiovascular status; monitor risk factors and actively manage during therapy. Uncontrolled or significant CVD (eg, recent MI, CHF, unstable angina, significant bradycardia). History of pancreatitis. Monitor for myelosuppression; withhold or reduce dose if occurs; perform CBCs every 2 weeks for 1^st 2 months then once monthly. Monitor serum lipase, liver function monthly or as clinically indicated; adjust dose appropriately. Monitor lipids and glucose periodically during first year, then yearly. Total gastrectomy (monitor frequently); consider dose increase or alternative therapy. Tumor lysis syndrome possible; maintain adequate hydration, correct uric acid levels prior to initiating therapy. Monitor for signs/symptoms of bleeding. Hereditary galactose intolerance, severe lactase deficiency, glucose-galactose malabsorption: not recommended. Monitor BCR-ABL transcript levels in patients eligible for treatment discontinuation or those who re-initiate treatment due to loss of molecular response, using an FDA authorized test (see full labeling). Monitor growth and development in children. Hepatic impairment: reduce dose. Embryo-fetal toxicity. Pregnancy: exclude status prior to initiation. Advise females of reproductive potential to use effective contraception during and for ≥14 days after the last dose. Nursing mothers: not recommended (during and for ≥14 days after the last dose).